HOW SHOULD I TAKE TARPEYO?
It is important to take TARPEYO exactly as your healthcare provider tells you. Your healthcare provider will decide how long you should take TARPEYO. Do not stop taking TARPEYO without first talking with your healthcare provider.
4 capsules of TARPEYO should be taken once a day and swallowed whole
Take TARPEYO in the morning, at least 1 hour before your morning meal
Don’t crush, chew, or open TARPEYO. Don’t eat grapefruit, or drink grapefruit juice, while on TARPEYO treatment
FREQUENTLY ASKED QUESTIONS
WHAT IS TARPEYO?
TARPEYO is a prescription medicine used to reduce levels of protein in the urine (proteinuria) in adults with IgA Nephropathy who are at high risk of disease progression. TARPEYO is the first therapy that was specifically designed for IgA Nephropathy.
WHEN WAS TARPEYO APPROVED?
TARPEYO was FDA-approved in December 2021 and is available by prescription. This approval is based on reduction in proteinuria. Confirmatory clinical trial results are needed to verify the clinical benefit of slowing kidney function decline.
HOW IS TARPEYO THOUGHT TO WORK?
TARPEYO is designed to deliver treatment to an area of the gut thought to play a role in IgA Nephropathy. Types of cells in the gut are thought to be responsible for the production of IgA1. These types of IgA1 can build up in the kidneys and cause IgA Nephropathy. TARPEYO can reduce the amount of this antibody.*
HOW IS TARPEYO DIFFERENT FROM OTHER STEROIDS I’VE BEEN PRESCRIBED FOR IgA NEPHROPATHY?
TARPEYO is the only FDA-approved treatment to reduce protein levels in the urine of patients with IgA Nephropathy and is designed for delivery to the area where the disease is thought to come from. Other steroids have not established efficacy and are not FDA approved for IgA Nephropathy.
WHAT DID TARPEYO CLINICAL STUDIES SHOW?
In a clinical study at 9 months, there was a significant 34% reduction in the level of protein in urine seen in the TARPEYO treated group compared with a 5% reduction in the placebo plus blood pressure medication group.†
The most common side effects (occurring in ≥10% of patients treated with TARPEYO at a higher incidence than blood pressure medication alone) were: high blood pressure; swelling of the lower legs, ankles, and feet; muscle cramp; and acne.
WHAT DOES A URINE ANALYSIS MEAN IN IgA NEPHROPATHY?
A routine urine test may be the first sign of IgAN if high levels of protein are seen. Large amounts of protein in the urine is called proteinuria. This helps measure kidney function in IgAN. Proteinuria was studied in the TARPEYO clinical trial.
*It has not been established to what extent the efficacy of TARPEYO is from local effects (in the gut) vs systemic effects (in circulation).
†In Part A of the TARPEYO clinical study, 97 patients received TARPEYO plus blood pressure medication, and 102 patients received placebo plus blood pressure medication.
ASK YOUR HEALTHCARE PROVIDER ABOUT TARPEYO
Here are some questions that can help you start the conversation.
What makes TARPEYO unique for people with IgA Nephropathy?
How does TARPEYO work?
What results might I expect?
What tests will you do to monitor if TARPEYO is working?
How do I take TARPEYO?
Is there anything I should avoid while taking TARPEYO?